PTEN and neoplasm: Importantly, we demonstrate that HIF1A is a critical factor enabling tumor cell survival in response to ADT and that genetic or pharmacological inhibition of HIF1A sensitizes Pten‐deficient lesions to castration, and leads to durable therapeutic responses.